ASLAN Pharmaceuticals Limited is a clinical-stage oncology and immunology focused biopharmaceutical company. The Company’s portfolio is comprised of one monoclonal antibody therapy targeting inflammatory disease and two small molecule inhibitors targeting oncology. The Company’s products include ASLAN004, ASLAN003 and Varlitinib. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor alpha1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. ASLAN003 is an inhibitor of human dihydroorotate dehydrogenase (DHODH), in acute myeloid leukemia (AML) and are exploring development in other solid tumors. Varlitinib is an oral, reversible small-molecule pan-HER inhibitor.
No valuation ratios available.
No company officers listed.
No insider trading activity.
Insider trading information report provided by Copyright © 2020. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.